Qube Research & Technologies LTD Ultragenyx Pharmaceutical Inc. Transaction History

Qube Research & Technologies LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$43.02 - $53.69 $27,618 - $34,468	642 New	642 $29,000
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $1.23 Million - $2.04 Million	30,774 New	30,774 $1.27 Million
Q3 2021 Nov 12, 2021	SELL	$77.92 - $102.4 $2.36 Million - $3.1 Million	-30,246 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$92.19 - $115.71 $2.36 Million - $2.96 Million	25,550 Added 544.08%	30,246 $2.88 Million
Q1 2021 May 14, 2021	SELL	$106.9 - $167.73 $1.27 Million - $1.99 Million	-11,876 Reduced 71.66%	4,696 $535,000
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $1.4 Million - $2.94 Million	16,572 New	16,572 $2.29 Million

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.